Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1528-1533

  Orgel, Etan ^a,b   Zung, Laura ^c   Ji, Lingyun ^d   Finklestein, Jerry ^a   Feusner, James ^e   Freyer, David R ^b,c  

^a MILLER CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

AML; Cardiotoxicity; Late effects

Indexed keywords

DAUNORUBICIN; DIGOXIN; ENALAPRIL; GEMTUZUMAB OZOGAMICIN; MILRINONE; MITOXANTRONE; RAZOXANE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARDIAC PATIENT; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART PROTECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISPANIC; HOSPITALIZED CHILD; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

AML; CARDIOTOXICITY; LATE EFFECTS;

ADOLESCENT; ADULT; ANTHRACYCLINES; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HISPANIC AMERICANS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VENTRICULAR REMODELING;

EID: 84880350212     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24498     Document Type: Article

References (47)

1. Pulte D, Gondos A, Brenner H. Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008; 100:1301-1309.
2. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28:2625-2634.
3. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19:2130-2138.
4. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 962. J Clin Oncol 2004; 22:4290-4301.
5. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249-1259.
6. National Cancer Institute Clinical Trials Database: Phase II/III Randomized Study of Bortezomib and Sorafenib Tosylate in Patients With De Novo Acute Myeloid Leukemia With or Without High Allelic Ratio FLT3/ITD Mutations. http://cancer.gov/clinicaltrials/COG-AAML 1031 (Last Accessed March 15, 2012).
7. National Cancer Institute Clinical Trials Database: Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia. http://cancer.gov/clinicaltrials/COG-AAML 0531 (Last Accessed March 15, 2012).
8. National Institute of Health Clinical Trials Database: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia. http://clinicaltrials.gov/show/NCT 00703820 (Last Accessed April 10, 2012).
9. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.
10. Brouwer CA, Postma A, Vonk JM, et al. Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer 2011; 47:2453-2462.
11. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 2007; 7:122-128.
12. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr Blood Cancer 2005; 44:600-606.
13. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33:S2-S7.
14. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 2001; 19:191-196.
15. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009; 15:392-397.
16. Abosoudah I, Greenberg ML, Ness KK, et al. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 2011; 57:467-472.
17. Cheung YF, Hong WJ, Chan GC, et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart 2010; 96:1137-1141.
18. Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007; 49:812-816.
19. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
20. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30:1042-1049.
21. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008; 26:3777-3784.
22. National Cancer Institute Clinical Trials Database: Phase II Pilot Study of Gemtuzumab Ozogamicin in Children With Newly Diagnosed Acute Myeloid Leukemia Undergoing Intensive Remission Induction and Intensification Therapy. http://cancer.gov/clinicaltrials/COG-AAML03P1 (Last Accessed October 12, 2012).
23. National Cancer Institute Clinical Trials Database: Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia. http://cancer.gov/clinicaltrials/COG-AAML 0531 (Last Accessed October 12, 2012).
24. Ewer M, Benjamin R, Yeh ETH. Chapter 152: Cardiac Complications. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E. Holland-Frei cancer medicine, 6th edition. Hamilton, ON: BC Decker; 2003. ISBN-10: 1-55009-213-8
25. The AML Collaborative Group. A systemic collaborative overview of randomized trials comparing idarubicin with daunorubicn (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103:100-109.
26. Kuczmarski R, Ogden C, Grummer-Strawn L, et al. CDC growth charts: United States. Advance data from vital and health statistics, Vol. 314. Hyattsville, MD: National Center for Health Statistics; 2000.
27. Temming P, Qureshi A, Hardt J, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer 2011; 56:625-630.
28. Creutzig U, Diekamp S, Zimmermann M, et al. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007; 48:651-662.
29. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20:1677-1682.
30. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0. Arcadia, CA: Children's Oncology Group; 2008. Available online: www.survivorshipguidelines.org (Last Accessed October 12, 2012).
31. Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012; 30:1050-1057.
32. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30:2876-2884.
33. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5:596-603.
34. Lipshultz SE, Cochran TR, Wilkinson JD. Screening for long-term cardiac status during cancer treatment. Circ Cardiovasc Imaging 2012; 5:555-558.
35. Weiss RB, Grillo-Lopez AJ, Marsoni S, et al. Amsacrine-associated cardiotoxicity: An analysis of 82 cases. J Clin Oncol 1986; 4:918-928.
36. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group cxperience. J Clin Oncol 1997; 15:1544-1552.
37. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J Clin Oncol 2012; 30:1415-1421.
38. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6:1321-1327.
39. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293:203-203.
40. Orgel E, Sposto R, Malvar J, et al. Extremes of weight are associated with increased treatment-related toxicity in high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2011; 118: Abstract # 3574.
41. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493-500.
42. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26:1106-1111.
43. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-961.
44. van Dalen EC, van den Berg H, Raphaël MF, et al. Should anthracyclines and dexrazoxane be used for children with cancer? Lancet Oncol 2011; 12:12-13.
45. van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 5:CD005006.
46. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004; 100:2052-2063.
47. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005; 46:795-802.